The significant burden that results from dengue virus infection combined with the absence of effective vaccines or drugs makes the development of novel therapeutics a high priority. We have previously identified disubstituted pyrimidines that inhibit dengue virus entry by binding to the pre-fusion E dimer on the virion surface, perhaps in the beta-octoglucoside binding pocket previously identified by Harrison and colleagues. Here, we propose to develop assays to identify other ligands of this site that can inhibit dengue virus entry. The subsequent high-throughput screening (HTS) effort and downstream activities are needed to interrogate the chemical diversity that can bind in this pocket, to generate additional lead compounds, and to elucidate the structural and mechanistic correlates of potent anti-dengue activity.
In Aim 1, we will use these compounds to develop a high-throughput fluorescence polarization assay to identify ligands of the dengue virus envelope protein that inhibit dengue virus infection.
In Aim 2, we propose to develop an assay to monitor bulk fusion of viral particles in vitro.
In Aim 3, we will validate our assay pipeline by performing a pilot screen. We will use assays developed in Aims 1 and 2 as well as other assays previously developed in our laboratory to characterize the mechanisms of action of compounds with activity against dengue virus. At the conclusion of this proposal, we anticipate having robust assays that are ready for high-throughput screening. The goal of these downstream HTS efforts is the development of molecular probes to study the structural and biochemical mechanisms of dengue entry, to validate the beta-octoglucoside pocket as a molecular target for inhibition of dengue entry, and to define the SAR governing the anti-dengue activity of ligands of the beta-octoglucoside pocket. In the longer term, this work will also contribute to our future goals of developing small molecule inhibitors of DV entry as preclinical candidates for anti-dengue drug discovery efforts.
Dengue virus is the most widespread mosquito-borne virus in the world today and the cause of significant human disease;however, there currently are no vaccines or specific antiviral therapies to prevent or to treat dengue virus infection. The proposed experiments will develop assays to identify small molecules that inhibit dengue virus by preventing the entry of dengue virus into a host cell.
| Lian, Wenlong; Jang, Jaebong; Potisopon, Supanee et al. (2018) Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. ACS Infect Dis 4:1395-1406 |
| de Wispelaere, Melissanne; Lian, Wenlong; Potisopon, Supanee et al. (2018) Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chem Biol 25:1006-1016.e8 |
| Pitts, Jared D; Li, Pi-Chun; de Wispelaere, Melissanne et al. (2017) Antiviral activity of N-(4-hydroxyphenyl) retinamide (4-HPR) against Zika virus. Antiviral Res 147:124-130 |
| Chou, Yi-Ying; Cuevas, Christian; Carocci, Margot et al. (2016) Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. J Virol 90:4494-4510 |
| Clark, Margaret J; Miduturu, Chandra; Schmidt, Aaron G et al. (2016) GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chem Biol 23:443-52 |
| Sundberg, Thomas B; Liang, Yanke; Wu, Huixian et al. (2016) Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function in Vivo. ACS Chem Biol 11:2105-11 |
| Villareal, Valerie A; Rodgers, Mary A; Costello, Deirdre A et al. (2015) Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses. Antiviral Res 124:110-21 |
| Inci, Fatih; Filippini, Chiara; Baday, Murat et al. (2015) Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics. Proc Natl Acad Sci U S A 112:E4354-63 |
